A comparison of genomic assays in determining risk of late recurrence and benefit of extended endocrine therapy (EET).

Authors

K Rague
L M. Rico
Eddy Yu MD, Lehigh Valley Health NetworkFollow
B Carter
T G. Frazier

Publication/Presentation Date

5-2017

Volume

35

Issue

15

Published In/Presented At

https://doi.org/10.1200/JCO.2017.35.15_suppl.e12045

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division, Hematology-Medical Oncology Division Fellows and Residents, Fellows and Residents

Document Type

Article